MBRX — Moleculin Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- $25.24m
- $17.69m
Annual cashflow statement for Moleculin Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.4 | -15.9 | -29 | -29.8 | -21.8 |
| Depreciation | |||||
| Non-Cash Items | -0.575 | -4.26 | 1.03 | 3.92 | -2.46 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.041 | 1.04 | 0.224 | 1.62 | 0.231 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -17.8 | -19 | -27.6 | -24.1 | -23.9 |
| Capital Expenditures | -0.376 | -0.019 | -0.067 | -0.124 | -0.013 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.002 | 0 | — | — | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.374 | -0.019 | -0.067 | -0.124 | -0.013 |
| Financing Cash Flow Items | -0.017 | -0.023 | -0.023 | 0.485 | -0.026 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 22.5 | 74.7 | -0.023 | 4.65 | 4.63 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.44 | 55.7 | -27.8 | -19.6 | -19.3 |